chrisvoncsefalvay/vaers-outcomes huggingface dataset:
1st dose in Apr2021, 2nd dose on18Jul2021; I was 130 time of shot im 118 now; not been able to get food down; yesterday my arm right went without feeling; sweating like crazy; This is a spontaneous report from a contactable consumer (patient).   A 49-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE), intramuscular, administered in arm left on 18Jul2021 (Lot number was not reported) (at the age of 49-year-old) as single dose for COVID-19 immunisation. Prior to vaccination the patient was not diagnosed with COVID-19 and since the vaccination the patient has not been tested for COVID-19.  Medical history was none. No known allergies. There were no concomitant medications. The patient previously received first dose of  BNT162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in arm left in Apr2021 (Lot number was not reported) (at the age of 49-year-old) as single dose for COVID-19 immunisation. The patient reported that: "I was 130 time of shot IM 118 now", "not been able to get food down", "yesterday my arm right went without feeling" and "sweating like crazy"  in 2021. No therapeutic measures were taken as a result of the events. The patient outcome of the events was not recovered.    The lot number for the vaccine [BNT162B2] was not provided and will be requested during follow up.
Around 09.50 at night, I started to feel chills and a feeling of cold for no apparent reason, and I had to go to bed because I could barely stand. Once in bed, I began to feel severe back pain, headache, and a progressive increase in fever to 103.5. I was taking Tylenol during the night and trying to hydrate myself, since I perceived that due to the fever, I was sweating frequently. The next day I also had a fever and a severe headache, but I was able to rest well, and today, Monday, I am already without apparent symptoms, beyond a feeling of moderate weakness.
This case was reported by a consumer via call center representative and described the occurrence of fever in a infant male patient who received PEDIARIX.  Co-suspect products included Rotavirus vaccine. Concomitant products included Hib vaccine and Pneumococcal vaccine. On 21st September 2016, the patient received the 1st dose of PEDIARIX and the 1st dose of Rotavirus vaccine (oral). On an unknown date, less than a year after receiving PEDIARIX and Rotavirus vaccine, the patient experienced fever and respiratory syncytial virus infection. The patient was treated with ibuprofen and TYLENOL. On an unknown date, the outcome of the fever and respiratory syncytial virus infection were unknown. The reporter considered the fever to be related to PEDIARIX. It was unknown if the reporter considered the respiratory syncytial virus infection to be related to PEDIARIX and Rotavirus vaccine. The reporter considered the fever to be probably related to Rotavirus vaccine. Additional details were provided as follows: This case was reported by the patient's mother. The reporter stated that the patient got his first set of vaccines. The patient received DTaP, Hep B, Hib, Polio, pneumococcal and rotavirus in 3 injections and one oral vaccine. After the vaccination the patient experienced a very high fever. Even while taking TYLENOL his fever was still 105 degree F. The patient was taken to the emergency room and administered Ibuprofen, which did not help bring his fever down. The reporter was not told the specific brand of vaccines that were administered, but she thought one was PEDIARIX. The patient had not received the 2nd dose of any of the vaccines as it was suspected that he had respiratory syncytial virus infection when his 2nd appointment was scheduled and the caller has not yet been able to make another appointment, till the time of reporting. The reporter spoke with the health department about the fever, and was advised that the fever was probably caused by the rotavirus vaccine. All the reporter's own research suggested that it was due to the DTaP.
Fever, swelling, erythema and pain in right thigh, pain and swelling increased and patient was unable to put weight on right leg.
On the 10th, I started to feel achy that morning. It seemed like it had a focal point in my right hip and thigh that was a deep shooting pain. It continued to be there. I have been taking Tylenol - 1000 mg once a day and sometimes I skip it because I don't want to hurt my liver  - so daily as needed.  It seems like my foot pain got worse during the time after the second dose and the week after. At this time it has plateaued - not getting worse - as long as I walk on the side of my foot, I'm okay. Can't walk on it in a regular way. My right hip and thigh is a continuous ache unless I take Tylenol and sometimes that wakes me up. If I lose sleep I get a migraine. I see the chiropractor weekly and the physical therapist weekly.
upper back ache; she also had a cough before receiving the vaccine and it got better; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (upper back ache) and COUGH (she also had a cough before receiving the vaccine and it got better) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced BACK PAIN (upper back ache) and COUGH (she also had a cough before receiving the vaccine and it got better). At the time of the report, BACK PAIN (upper back ache) and COUGH (she also had a cough before receiving the vaccine and it got better) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  No treatment information was provided.  Very limited information regarding this events has been provided at this time. Further information has been requested. Company assessed the events to be unlikely related to company product.   Reporter did not allow further contact; Sender's Comments: Very limited information regarding this events has been provided at this time. Further information has been requested. Company assessed the events to be unlikely related to company product.
arm was swollen under the injection site like a ball; arm was hot to the touch; arm was really itchy; swelling of the arm/arm was swollen; This spontaneous case was reported by a consumer and describes the occurrence of INJECTION SITE MASS (arm was swollen under the injection site like a ball), VACCINATION SITE WARMTH (arm was hot to the touch), VACCINATION SITE PRURITUS (arm was really itchy) and VACCINATION SITE SWELLING (swelling of the arm/arm was swollen) in a 28-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. MLs-319813_r) for COVID-19 vaccination.     No Medical History information was reported.  On 04-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 04-Jan-2021, the patient experienced VACCINATION SITE SWELLING (swelling of the arm/arm was swollen).   On 12-Jan-2021, the patient experienced INJECTION SITE MASS (arm was swollen under the injection site like a ball), VACCINATION SITE WARMTH (arm was hot to the touch) and VACCINATION SITE PRURITUS (arm was really itchy).   On 07-Jan-2021, VACCINATION SITE SWELLING (swelling of the arm/arm was swollen) had resolved. At the time of the report, INJECTION SITE MASS (arm was swollen under the injection site like a ball), VACCINATION SITE WARMTH (arm was hot to the touch) and VACCINATION SITE PRURITUS (arm was really itchy) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   Concomitant product use was not provided by the reporter. No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Initially on day 1, red warm and hot with stinging sensation at injection site.  Temp 102. Used Ice pain and Ibuprofen. Those symptoms resolved within 48 hours.  11/11/21 Symptoms returned of L arm rash/burning with fingers tingling with L arm feeling very heavy,  Red firm induration at site of injection measuring 3.5 x 6 cm.  Left leg below knee cap, feels like waves of intense electric shocks. Applying pressure seems to help. Fullness sensation behind knee.
On Wednesday, March 24th approximately 4:00 PM I started having severe chest pain, shortness of breath and tingling in my face. After about 40 minutes of severe chest pains and shortness of breath and tingling in my face I took 2 81 mg baby aspirin called 911 was advised to take two more 81 mg baby aspirin. Transported to ER.
most likely not an adverse to the vaccine however, patient did experience a hypglcyemic event afer a covid vaccine with pfizer bivalant booster.Patient had in implanted glucometer on her left arm that read on the low 50s following a the vaccine. On site RN contacted on call MD and he advised to give a glucose tab.
4-6 hrs p/vax pt had 1 1/2 hrs of persistant crying that was high pitched; t98; pt also had swollen, red, tender lt leg (area of DTP vax);
Back pain; Mobility issues; Sore arm after vaccination; Bone spur; This spontaneous case was reported by a consumer and describes the occurrence of BACK PAIN (Back pain), MOBILITY DECREASED (Mobility issues), EXOSTOSIS (Bone spur) and VACCINATION SITE PAIN (Sore arm after vaccination) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Rheumatoid arthritis.    No Medical History information was reported.   On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 12-Mar-2021, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose once a week. On 12-Jan-2022, ADALIMUMAB (HUMIRA) (Subcutaneous) dosage was changed to at an unspecified dose once a week. On 29-Mar-2021, the patient experienced EXOSTOSIS (Bone spur). On an unknown date, the patient experienced BACK PAIN (Back pain), MOBILITY DECREASED (Mobility issues) and VACCINATION SITE PAIN (Sore arm after vaccination). At the time of the report, BACK PAIN (Back pain), MOBILITY DECREASED (Mobility issues), EXOSTOSIS (Bone spur) and VACCINATION SITE PAIN (Sore arm after vaccination) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 29-Mar-2021, Magnetic resonance imaging: Bone spurs.         Concomitant product use was not provided by the reporter.  On unknown dates, the patient experienced back pain, sore arm, and mobility issues. On 29-Mar-2021, the patient had bone spurs. No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2022-623336 (Patient Link).   Reporter did not allow further contact
Kinrix instead of the recommeded Dtap-IPV; Kinrix + Underage administration; This non-serious case was reported by a other health professional via call center representative and described the occurrence of wrong vaccine administered in a 4-month-old female patient who received DTPa-IPV (Kinrix) (batch number C472T, expiry date 22-MAR-2023) for prophylaxis.   On an unknown date, the patient received Kinrix. On an unknown date, an unknown time after receiving Kinrix, the patient experienced wrong vaccine administered (Verbatim: Kinrix instead of the recommeded Dtap-IPV) and inappropriate age at vaccine administration (Verbatim: Kinrix + Underage administration). The outcome of the wrong vaccine administered and inappropriate age at vaccine administration were unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK receipt date: 10-May-2023 No date of administration was gathered. The vaccine administration facility was the same as primary reporter. The reporter consented to follow-up. The patient received a dose of Kinrix instead of the recommended Dtap-IPV vaccine at inappropriate age, which led to wrong vaccine administered and inappropriate age at vaccine administration.
Admitted to hospital on 7/9/2021 with shortness of breath,  and fatigue.. Hypoxic on admit.  AKI.  Required intubation and mechanical ventilation 7/25/2021. Transitioned to comfort measures only on 8/17/21 and expired.
no adverse event; earlier than the recommended doging interval; This spontaneous report was received from a Nurse and refers to a patient of unknown age and gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported.  On 15-JUL-2022, the patient was vaccinated with the first dose of hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) injection, 0.5 ml, lot #W000244, expiration date: 09-AUG-2023, administered for prophylaxis (strength, and route of administration were not provided). The second dose was given on 17-AUG-2022, and the third dose was administered on 20-OCT-2022, administered earlier than the recommended dosing interval (Inappropriate schedule of vaccine administered) at the reporting time, no adverse event was experienced.
t101, ping pong ball size-hot lump in lt thigh x 3 days;excessive sleep x 2 days & more naps subsequent days;startle reflex turned into clusters of them dx infantile spasms;given meds still abn brain activity;site of inj swollen;paralysis
Nausea and Mild Diarrhea contuning now today over 10 days later. Treated Diarrhea with Pepto Bismol daily 8 doses which has helped the Diarrhea but not the Nausea which I rate on a 10 scale as a 5.
Father came in with 4-year-old requesting 2nd dose of Pfizer vaccine series. Pharmacist incorrectly confirmed the monovalent/2nd dose Pfizer vaccines were in stock (when in fact, it was the bivalent/3rd dose Pfizer vaccines in stock). The bivalent/3rd dose Pfizer vaccine was diluted, drawn up (by pharmacist), and administered (by intern). When typing the vaccine, there was confusion as to which NDC to select because the on-hand quantity for the monovalent Pfizer vaccine was zero. Pharmacist realized the mistake, notified the father of the mistake, assured the father that the Pfizer manufacturer would be contacted for proper protocol (i.e., should the 4-year-old still receive a 3rd dose after 8 weeks if the 2nd dose was bypassed and the 3rd dose was already administered?), and the patient?s doctor would also be notified.
Fever chills and low grade fever at bedtime, slight throat irritation with dry cough Narrative: Low grade fever, body aches, chills, body aches are the worse.
Had the second shot and I have got a little bit of fever; This is a spontaneous report from a contactable consumer or other non-HCP (patient). A patient of unspecified age and gender received second dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number- UNKNOWN) via an unspecified route of administration on an unspecified date as dose 2, single for COVID-19 immunization. Medical history and concomitant medications were not reported. Historical vaccine included first dose of BNT162b2 (PFIZER BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number- UNKNOWN) via an unspecified route of administration on an unspecified date as dose 1, single for COVID-19 immunization. The patient experienced had the second shot and had got a little bit of fever. Patient stated was it common to get a fever from the second shot. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
ran a 102.5 fever; chills; joints ached horribly; nauseated; had no appetite; This is a spontaneous report received from a non-contactable consumer (Patient).  A male patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number not reported), via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. The patient historical vaccine included first dose of BNT162B2 for COVID-19 immunization. On an unspecified date, the patient ran a 102.5 fever, chills, joints ached horribly, nauseated and had no appetite for the better part of 4 days. The patient woke up on day 5 and felt perfectly fine. The second dose of Pfizer took him out for nearly a week. The outcome for events fever, chills, joints ached horribly, nauseated and had no appetite was recovered on an unspecified date.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Severe myalgia followed the vaccine by several hours and peaked at 24-48 hours total CK on day 3 was 296 (0-200). Aldolase and anti hep A were normal and negative.
ACHES; This spontaneous report received from a consumer concerned a female of unspecified age. The patient's weight, height, and medical history were not reported.The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 13-MAR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 13-MAR-2021, the subject experienced aches. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from aches on MAR-2021. This report was non-serious. This case, from the same reporter is linked to 20210328609.
This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (55 patients received a dose of a vial after 12 hours of initial puncture) in a 24-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 939902) for COVID-19 vaccination. No Medical History information was reported. On 03-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (55 patients received a dose of a vial after 12 hours of initial puncture). On 03-Dec-2021, EXPIRED PRODUCT ADMINISTERED (55 patients received a dose of a vial after 12 hours of initial puncture) had resolved. Not Provided. For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments. Vial was punctured on  11-Nov-21, dose was given, kept in refrigerator after puncture. It was reported that there were two vials that were punctured and used some time between June and 5 -November , but reporter can't back track those dates, they were written on the vials themselves, which were disposed of. It just came to their attention that the vials were being used past the recommended 12 hour post puncture time. No concomitant medication was provided. No treatment medication was provided. This case was linked to MOD-2021-418964 (Patient Link).
This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On 10-MAR-2017, the patient was vaccinated with improperly stored dose of M-M-R II recombinant human albumin (RHA) lot # M002418 with an expiration date 12-JAN-2018 for prophylaxis (dose, route of administration and anatomical location were not reported). There was no adverse effect reported. Administered dose of M-M-R II experienced the temperature excursion of -14.4 degrees Celsius for 54 minutes. There was no previous temperature excursion reported. A digital data logger was involved. This is one of several reports received from the same reporter. Additional information is not expected, all information has already been obtained.; Sender's Comments: US-009507513-1611USA011831: US-009507513-1611USA004113: US-009507513-1705USA009742: Original Case : 1705USA009742.
APPROX TWO WEEKS AFTER HER VACCINATION SHE DEVELOPED MUSCLE SORENESS IN HER UPPER ARM AND IT HAS NOT GONE AWAY.
At 3:00 am on 1/26/2021, I woke up shaking with chills, had a fever of 103 degrees, felt nauseous and had a severe headache.  This continued for about 4 hours after which time the symptoms subsided.  Throughout the day I had a mild headache and my temperature did go back to normal.
NAUSEA; HEADACHE; INJECTION SITE PAIN; BODY ACHE; ARM HURT; CHILLS; JOINT PAIN; MYALGIA; This spontaneous report received from a patient concerned a 62 year old female. The patient's weight was 125 pounds, and height was 174 centimeters. The patient's concurrent conditions included no alcohol user, and non smoker. The patient experienced drug allergy when treated with tetracycline.  The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1802068 expiry: 25/MAY/2021) dose was not reported, administered on 10-MAR-2021 11:00 for prophylactic vaccination.  Concomitant medications included ascorbic acid/calcium/minerals nos/retinol/tocopheryl acetate/vitamin b nos/vitamins nos/zinc for drug used for unknown indication, calcium carbonate/colecalciferol for drug used for unknown indication, vitamin c for drug used for unknown indication, alendronate sodium for osteoporosis, nebivolol hydrochloride for slow heart down, aloe vera, and chondroitin sulfate/collagen/glucosamine. On 10-MAR-2021, the subject experienced body ache. On 10-MAR-2021, the subject experienced arm hurt. On 10-MAR-2021, the subject experienced chills. On 10-MAR-2021, the subject experienced joint pain. On 10-MAR-2021, the subject experienced myalgia. On 10-MAR-2021 15:00, the subject experienced nausea. On 10-MAR-2021 12:30, the subject experienced headache. On 10-MAR-2021, the subject experienced injection site pain.  The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from body ache, arm hurt, chills, myalgia, nausea, joint pain, and injection site pain. and headache on 11-MAR-2021 This report was non-serious.
4/3/03 received adult TD for puncture wound on foot. States after receiving shot felt a warm rush and questioned if it was nerves, after noted prickly feeling back of neck seemed as getting more itchy-noted rash ? shoulders and then came back to clinic and rash extended up neck and swelling under eyes. Came back to clinic evaluations and received Benadryl shot. Pt received Medrol dose and med for itching. 4/11/03 minimal rash no ? hot ? its ?